Linagliptin
| CAS No. | 668270-12-0 |
|---|---|
| MDL No. | MFCD14635356 |
| MF | C25H28N8O2 |
| MW | 472.50 |
| InChI Key | LTXREWYXXSTFRX-QGZVFWFLSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Linagliptin is a 7H-xanthine derivative with substituents at positions 1, 3, 7, and 8: (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl, and 3-aminopiperidin-1-yl, respectively (the R-enantiomer). It is used in the treatment of type II diabetes, acting as a dipeptidyl-peptidase IV inhibitor and hypoglycemic agent. It belongs to quinazolines and aminopiperidines and is functionally related to 7H-xanthines.
| CAS No. | 668270-12-0 |
|---|---|
| Product Name | Linagliptin |
Biological Targets
DPP4
Associated Conditions
non-small cell lung carcinoma·gastroesophageal junction adenocarcinoma·gastric adenocarcinoma·hypertension·COVID-19·
* The information provided here is compiled from public sources and is for reference only.
